Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe Asthma

Rhea-AI Summary

Upstream Bio (Nasdaq: UPB) will webcast top-line results from the Phase 2 VALIANT trial of verekitug on February 11, 2026 at 8:00 a.m. ET. The global, randomized, double-blind, placebo-controlled trial enrolled 478 patients with severe asthma and tested three dosing regimens versus placebo for up to 60 weeks.

Live access and a replay will be available on the company’s investor events page.

News Market Reaction – UPB

-47.18% 7.1x vol

98 alerts

-47.18% News Effect

+15.7% Peak Tracked

-54.2% Trough Tracked

-$1.38B Valuation Impact

$1.54B Market Cap

7.1x Rel. Volume

On the day this news was published, UPB declined 47.18%, reflecting a significant negative market reaction. Argus tracked a peak move of +15.7% during that session. Argus tracked a trough of -54.2% from its starting point during tracking. Our momentum scanner triggered 98 alerts that day, indicating high trading interest and price volatility. This price movement removed approximately $1.38B from the company's valuation, bringing the market cap to $1.54B at that time. Trading volume was exceptionally heavy at 7.1x the daily average, suggesting significant selling pressure.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

VALIANT trial phase: Phase 2 Patients enrolled: 478 patients Treatment duration: up to 60 weeks +5 more

8 metrics

VALIANT trial phase Phase 2 VALIANT severe asthma study of verekitug

Patients enrolled 478 patients Severe asthma VALIANT Phase 2 trial population

Treatment duration up to 60 weeks VALIANT safety and efficacy evaluation period

Minimum treatment 24 weeks Minimum verekitug treatment duration in VALIANT

Dose level 100 mg One verekitug dosing arm every 24 or 12 weeks

Dose level 400 mg One verekitug dosing arm every 24 weeks

Dosing interval every 12 or 24 weeks Subcutaneous verekitug administration schedule

Webcast time 8:00 a.m. ET Top-line VALIANT results webcast on Feb 11, 2026

Market Reality Check

Price: $8.78 Vol: Volume 814,002 vs 20-day ...

normal vol

$8.78 Last Close

Volume Volume 814,002 vs 20-day average 624,959, showing elevated activity ahead of the VALIANT data webcast. normal

Technical Price at 27.81, trading above the 200-day MA of 19.15 going into the Phase 2 asthma update.

Peers on Argus

UPB gained 6.47% while close peers were mixed: SYRE -2.1%, QURE -3.29%, RAPP +3....

UPB gained 6.47% while close peers were mixed: SYRE -2.1%, QURE -3.29%, RAPP +3.44%, TRML 0%, VERV -0.09%, indicating a stock-specific move tied to the VALIANT webcast.

Historical Context

5 past events · Latest: Jan 05 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 05	Conference presentation	Neutral	-3.5%	Announcement of J.P. Morgan Healthcare Conference presentation and webcast access details.
Nov 25	Investor conferences	Neutral	+10.7%	Participation in December 2025 healthcare investor conferences with webcast availability.
Nov 05	Earnings and pipeline	Positive	-4.3%	Q3 2025 financials and positive Phase 2 VIBRANT CRSwNP data plus VALIANT/VENTURE updates.
Oct 31	Investor outreach	Neutral	+0.3%	November 2025 investor events and webcasts focused on the company’s story.
Sep 30	Mechanistic data	Positive	+8.5%	Presentation of structural/mechanistic verekitug data and prior positive Phase 2 CRSwNP results.

Pattern Detected

UPB has shown strong positive reactions to scientific/clinical data, while broader corporate and earnings updates have produced mixed or negative moves.

Recent Company History

Recent news emphasizes verekitug’s progression across Phase 2 programs. Positive mechanistic and clinical data in CRSwNP were highlighted on Sep 30, 2025, and operational/financial updates on Nov 5, 2025 detailed funding through 2027 and multiple Phase 2 trials. Investor conference participation in late 2025 and early 2026 has been frequent. Today’s announcement of a webcast for top-line VALIANT severe asthma results in 478 patients follows prior guidance that these data were expected in Q1 2026, marking a key upcoming clinical catalyst.

Market Pulse Summary

The stock dropped -47.2% in the session following this news. A negative reaction despite this schedu...

Analysis

The stock dropped -47.2% in the session following this news. A negative reaction despite this scheduling announcement would contrast with the generally constructive backdrop for verekitug. The VALIANT trial covers 478 severe asthma patients over up to 60 weeks, making the upcoming webcast a key inflection point. Prior news has produced mixed moves, including downside following earnings. A sharp decline could reflect heightened expectations into the readout and concern that forthcoming data might not match prior CRSwNP successes.

Key Terms

phase 2, randomized, double-blind, placebo-controlled, +4 more

8 terms

phase 2 medical

"The VALIANT trial (NCT06196879) is a Phase 2 global, randomized..."

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

randomized medical

"is a Phase 2 global, randomized, double-blind, placebo-controlled..."

Randomized means participants or units in a study are assigned to different groups by chance rather than by choice, like flipping a coin to decide who gets a new treatment and who gets a comparison. For investors, randomized designs matter because they reduce bias and make results more trustworthy, so outcomes from randomized studies carry more weight when assessing regulatory approval, commercial prospects, and the risk that trial results will change a company’s valuation.

double-blind medical

"Phase 2 global, randomized, double-blind, placebo-controlled, dose-ranging..."

A double-blind process means that neither the people conducting an activity nor the people involved know certain key details, such as who is receiving a treatment or a placebo. This approach helps prevent bias from influencing the results, making the outcome more trustworthy. For investors, it ensures that decisions or judgments are based on unbiased information rather than preconceived opinions or expectations.

placebo-controlled medical

"randomized, double-blind, placebo-controlled, dose-ranging, parallel group..."

"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.

dose-ranging medical

"double-blind, placebo-controlled, dose-ranging, parallel group clinical trial..."

A dose-ranging study is a clinical trial that tests multiple amounts of a drug to find what dose works best and is safest, much like trying different spice levels in a recipe to get the right balance. For investors, results clarify whether a medicine is effective at practical doses, how likely it is to win regulatory approval, what side effects to expect, and how the treatment might be priced and used in the market.

parallel group medical

"placebo-controlled, dose-ranging, parallel group clinical trial that evaluated..."

A parallel group is a collection of companies or entities that operate independently but share similar functions or purposes within a larger organization or industry. For investors, understanding these groups is important because they can influence overall performance, risk, and strategic decisions, much like different branches of a company that work separately but contribute to the whole. Recognizing these groups helps in assessing the stability and potential of investments across related businesses.

subcutaneously medical

"or placebo, administered subcutaneously."

Given or delivered beneath the skin into the fatty layer just under the surface, usually by injection or a small device. For investors, whether a medicine is given subcutaneously affects how easy it is for patients to use, how often doses are needed, and the cost and complexity of manufacturing and regulation—think of it like placing a slow-release patch under a carpet instead of pouring medicine on top of it, which changes convenience and ongoing demand.

thymic stromal lymphopoietin (tslp) medical

"targets and inhibits the thymic stromal lymphopoietin (TSLP) receptor..."

Thymic stromal lymphopoietin (TSLP) is a small signaling protein produced by certain cells that tells the immune system to start or heighten inflammatory responses, especially in the airways and skin. Investors care because TSLP is a clear drug target and potential biomarker—blocking or measuring it can change how chronic allergic, asthma, and other inflammatory conditions are treated, affecting drug development paths, regulatory reviews, and commercial prospects much like flipping a thermostat can change a whole room’s climate.

AI-generated analysis. Not financial advice.

– Webcast to be held Wednesday, February 11, 2026, at 8:00 a.m. ET –

WALTHAM, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced it will report top-line results from the Phase 2 VALIANT trial of verekitug, the only known antagonist currently in clinical development that targets and inhibits the thymic stromal lymphopoietin (TSLP) receptor, on Wednesday, February 11, 2026 at 8:00 a.m. ET.

The VALIANT trial (NCT06196879) is a Phase 2 global, randomized, double-blind, placebo-controlled, dose-ranging, parallel group clinical trial that evaluated the safety and efficacy of verekitug for up to 60 weeks, with a minimum of 24 weeks of treatment, in 478 patients with severe asthma. Participants were randomized into one of four groups, receiving either 100 mg of verekitug every 24 weeks, 400 mg of verekitug every 24 weeks, 100 mg of verekitug every 12 weeks, or placebo, administered subcutaneously.

Webcast Information
Upstream Bio’s webcast to discuss the top-line results from the Phase 2 VALIANT trial will begin Wednesday, February 11, 2026, at 8:00 a.m. ET. The live webcast can be accessed via this link or on the Events tab on the Investors section of the Company’s website at https://investors.upstreambio.com/news-events/events. A replay of the webcast will be available on the website following the call.

About Upstream Bio
Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist currently in clinical development that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. The Company has advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma, and chronic obstructive pulmonary disease (COPD). Upstream Bio’s team is committed to maximizing verekitug’s unique attributes to address the substantial unmet needs for patients underserved by today’s standard of care. To learn more, please visit www.upstreambio.com.

Investor and Media Contact:
Meggan Buckwell
Director, Corporate Communications and Investor Relations
ir@upstreambio.com

FAQ

When will Upstream Bio (UPB) report the Phase 2 VALIANT top-line results?

Upstream Bio will report Phase 2 VALIANT top-line results on February 11, 2026 at 8:00 a.m. ET. According to the company, the event will be presented via a live webcast with a replay available on the investor events page.

How many patients and what design did the VALIANT trial (UPB) use?

The VALIANT trial enrolled 478 patients in a randomized, double-blind, placebo-controlled, dose-ranging design. According to the company, the study evaluated safety and efficacy of verekitug over up to 60 weeks with a minimum of 24 weeks of treatment.

What doses of verekitug were evaluated in the UPB Phase 2 VALIANT trial?

VALIANT tested three dosing regimens: 100 mg every 24 weeks, 400 mg every 24 weeks, and 100 mg every 12 weeks, plus placebo. According to the company, all doses were administered subcutaneously in the randomized, parallel-group trial.

How can investors access Upstream Bio's webcast for the VALIANT results (UPB)?

Investors can join the live webcast via the company’s investor events page or the provided webcast link on February 11, 2026 at 8:00 a.m. ET. According to the company, a replay will be posted on the events tab after the call.